DCGI - NewsroomPost

India launches investigation into 4 cough syrups after WHO warns on death of 66 children in Gambia

India launches investigation into 4 cough syrups after WHO warns on death of 66 children in Gambia

Ayushi Sikarwar

Corbevax COVID-19 vaccine gets DCGI’s nod for children aged 5-12

Corbevax COVID-19 vaccine gets DCGI’s nod for children aged 5-12

ANI

DCGI grants EUA to ZycovD COVID vaccine for two-dose regimen for children above 12

DCGI grants EUA to ZycovD COVID vaccine for two-dose regimen for children above 12

ANI

DCGI gives emergency use authorisation to Covaxin for 6-12 age group

DCGI gives emergency use authorisation to Covaxin for 6-12 age group

ANI

DCGI gives final approval to COVID-19 vaccine Corbevax for 12-18 year olds

DCGI gives final approval to COVID-19 vaccine Corbevax for 12-18 year olds

ANI

84-yr-old Haryana man, first in India to get antibody cocktail against Covid-19 mutant

84-yr-old Haryana man, first in India to get antibody cocktail against Covid-19 mutant

ANI

Covaxin phase II/III clinical trials for 2-18 age group to begin in 10-12 days: Govt

Covaxin phase II/III clinical trials for 2-18 age group to begin in 10-12 days: Govt

Newsroom Staff

Vaccines approved are ‘110 % safe,’ says DCGI Chief VG Somani

Vaccines approved are ‘110 % safe,’ says DCGI Chief VG Somani

Newsroom Staff

Covid-19 Vaccines are 110 % safe, says Drug Controller General of India

Covid-19 Vaccines are 110 % safe, says Drug Controller General of India

Newsroom Staff

Pfizer India seeks emergency use authorisation from DCGI for its COVID-19 vaccine in the country

Pfizer India seeks emergency use authorisation from DCGI for its COVID-19 vaccine in the country

Newsroom Staff

© 2024, All Rights Reserved by Headlong Newsroom Post India Private Limited